 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- || Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Jul 16, 2021
P1, N=212, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024
- || Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Apr 1, 2021
P1, N=212, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Oct 2023 --> Jan 2024 | Trial primary completion date: Oct 2023 --> Jan 2024 Recruiting --> Active, not recruiting
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2021
P1b, N=120, Recruiting, Sponsor: Daiichi Sankyo, Inc.
Recruiting --> Active, not recruiting N=74 --> 120 | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Mar 2023
- ||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment open, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 11, 2020
P1b, N=74, Recruiting, Sponsor: Daiichi Sankyo, Inc.
N=74 --> 120 | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- ||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
New P1 trial, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 2, 2020
P1b, N=74, Not yet recruiting, Sponsor: Daiichi Sankyo, Inc.
- ||| Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Jul 26, 2020
P1, N=257, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment open, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Jun 25, 2020
P1b/2, N=220, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Apr 30, 2020
P1, N=257, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Oct 2023 | Trial primary completion date: Dec 2020 --> Oct 2023
- ||| Imfinzi (durvalumab) / AstraZeneca
New P1 trial, Combination therapy, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Jan 28, 2019
P1, N=200, Recruiting, Sponsor: AstraZeneca